An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease

Mohammad Abul Kalam Azad Khan; Kabirul Hasan Bin Rakib; Md. Saiful Islam Patwary; Mohammad Mahmudur Rahman Chowdhury; Abu Salah Mohammamed Sirajum Munir; Sohel Ahmed; Mohammad Ashif Iqbal; Mohammad Mushahidul Islam; Md. Abdur Rahim

doi:doi:10.11648/j.ajim.20210905.14

An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease

Mohammad Abul Kalam Azad Khan, Kabirul Hasan Bin Rakib, Md. Saiful Islam Patwary, Mohammad Mahmudur Rahman Chowdhury, Abu Salah Mohammamed Sirajum Munir, Sohel Ahmed, Mohammad Ashif Iqbal, Mohammad Mushahidul Islam, Md. Abdur Rahim

Published in American Journal of Internal Medicine (Volume 9, Issue 5)

Received: 3 October 2020 Accepted: 31 August 2021 Published: 12 October 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Inhaled corticosteroids effective medications for the treatment of asthma. Higher doses of inhaled fluticasone (1000 μgm / day) are commonly used in COPD. Such high doses have been associate with significant systemic effects such as pneumonia, glaucoma, cataracts, adrenal suppression and accelerated bone turnover. Aim of the study: The aim of the study was to evaluate the association between different doses of inhaled corticosteroids (Fluticasone Propionate µgm / day) and glycaemic status in Patients with Chronic Obstructive Pulmonary Disease. Material & Methods: This was a cross-sectional analytical study. This study was conducted at the department of Internal Medicine in Bangobandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, during May, 2016-April, 2017. The protocol of this study was approved by IRB and ethical committee. A total of 80 patients with COPD were included in this study, of them clinically diagnosed 40 consecutive COPD patients who were receiving both bronchodilator & inhaled corticosteroids were recruited as case group and clinically diagnosed 40 consecutive COPD patients receiving only bronchodilator without inhaled corticosteroid/systemic steroid were recruited as control, group. Spirometry was done for confirmation and staging of COPD according to GOLD at indoor and OPD patients of Department of Internal Medicine, BSMMU. Results: In case group, the inhaled corticosteroid dose (5000) was counted 02 (5%) and the mean of FPG value was 6.25±1.34, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of FPG value was 5.7±1.58, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of FPG value was 6.58±2.24. The total FPG mean of the doses was 5.97±1.78. Among case group according to inhaled corticosteroid dose in case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of 2HABF value was 9.65±3.18, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of 2HABF value was 8.71±2.84, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of 2HABF value was 9.51±2.9. The total mean of 2HABF value of the doses was 8.98±2.82. In case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of HbA1C value was 5.85±1.06, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of HbA1C value was 6.07±0.7, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of HbA1C value was 6.7±0.74. The total mean of HbA1C value of the doses was 6.23±0.77. Conclusion: We had found that 32% of cases and 7.5% of control group were diagnosed as diabetic when fasting plasma glucose taken into account, while in case of 2 hours after breakfast plasma sugar the number were 32.5% and 10% respectively and in case of HbA1c the number were 23.5% and 10% respectively.

Published in	American Journal of Internal Medicine (Volume 9, Issue 5)
DOI	10.11648/j.ajim.20210905.14
Page(s)	236-243
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Inhaled Corticosteroids, Glycaemic Status, COPD, Inhaled Corticosteroid Dose

References

[1]	Postma DS and Calverley P., 2009. Inhaled corticosteroids in COPD: a case in favour. European Respiratory Journal, 34, 10-12.
[2]	Rabe et al., 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory Critical Care Medicine, 176, 532–55.
[3]	Corrado A and Rossi A., 2012. How far is real life from COPD therapy guidelines? An Italian observational study. Respiratory Medicine 106, 989–97.
[4]	Wedzicha JA et al., 2008. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory Critical Care Medicine, 177, 19–26.
[5]	Garbe E. et al (2007) Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs, Annals of Internal Medicine, 146 (9): 657-65.
[6]	Mannino DM et al., 2008. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. European Respiratory Journal, 32, 962-9.
[7]	Calverley PM et al (2007), A Pooled Analysis of FEV₁ Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo, 131 (3): 682-689.
[8]	Slatore, Christopher G., Chris L. Bryson, and David H. Au. "The association of inhaled corticosteroid use with serum glucose concentration in a large cohort." The American journal of medicine 122.5 (2009): 472-478.
[9]	Faul et al: The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clinical Med Res 2009; 7: 14-20.
[10]	Suissa S, Kezouh A and Ernst P., 2010. Inhaled corticosteroids and the risks of diabetes onset and progression. American Journal of Medicine, 123, 1001e6.
[11]	Matthijnssens, Jelle, et al. "Higher proportion of G2P [4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P [4] rotaviruses." Clinical Microbiology and Infection 20.10 (2014): O702-O710.
[12]	Faul et al (2002), Alterations in Airway Inflammation and Lung Function during Corticosteroid Therapy for Atopic Asthma. The Chest-121: 1414-1420.
[13]	Mirrakhimov, et al. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 11, 132 (2012). https://doi.org/10.1186/1475-2840-11-132
[14]	Rana J et al., 2004. Pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care, 27, 2478–84.
[15]	Kian et al (2012). Graphene Photonics, Plasmonics, and Broadband Optoelectronic Devices, Nano 6 (5): 3677-3694.
[16]	Christopher et al. (2015), Association of COPD with risk for pulmonary infections requiring hospitalization in HIV-infected Veterans, PMC (2015): 70 (3): 280-288.
[17]	Dendukuri et al, Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study, POLOS ONE: 11 (19), 2016: e0162903.

Cite This Article

Plain Text BibTeX RIS

APA Style

Mohammad Abul Kalam Azad Khan, Kabirul Hasan Bin Rakib, Md. Saiful Islam Patwary, Mohammad Mahmudur Rahman Chowdhury, Abu Salah Mohammamed Sirajum Munir, et al. (2021). An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Internal Medicine, 9(5), 236-243. https://doi.org/10.11648/j.ajim.20210905.14

Copy | Download

ACS Style

Mohammad Abul Kalam Azad Khan; Kabirul Hasan Bin Rakib; Md. Saiful Islam Patwary; Mohammad Mahmudur Rahman Chowdhury; Abu Salah Mohammamed Sirajum Munir, et al. An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Intern. Med. 2021, 9(5), 236-243. doi: 10.11648/j.ajim.20210905.14

Copy | Download

AMA Style

Mohammad Abul Kalam Azad Khan, Kabirul Hasan Bin Rakib, Md. Saiful Islam Patwary, Mohammad Mahmudur Rahman Chowdhury, Abu Salah Mohammamed Sirajum Munir, et al. An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease. Am J Intern Med. 2021;9(5):236-243. doi: 10.11648/j.ajim.20210905.14

Copy | Download

@article{10.11648/j.ajim.20210905.14,
  author = {Mohammad Abul Kalam Azad Khan and Kabirul Hasan Bin Rakib and Md. Saiful Islam Patwary and Mohammad Mahmudur Rahman Chowdhury and Abu Salah Mohammamed Sirajum Munir and Sohel Ahmed and Mohammad Ashif Iqbal and Mohammad Mushahidul Islam and Md. Abdur Rahim},
  title = {An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease},
  journal = {American Journal of Internal Medicine},
  volume = {9},
  number = {5},
  pages = {236-243},
  doi = {10.11648/j.ajim.20210905.14},
  url = {https://doi.org/10.11648/j.ajim.20210905.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20210905.14},
  abstract = {Introduction: Inhaled corticosteroids effective medications for the treatment of asthma. Higher doses of inhaled fluticasone (1000 μgm / day) are commonly used in COPD. Such high doses have been associate with significant systemic effects such as pneumonia, glaucoma, cataracts, adrenal suppression and accelerated bone turnover. Aim of the study: The aim of the study was to evaluate the association between different doses of inhaled corticosteroids (Fluticasone Propionate µgm / day) and glycaemic status in Patients with Chronic Obstructive Pulmonary Disease. Material & Methods: This was a cross-sectional analytical study. This study was conducted at the department of Internal Medicine in Bangobandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, during May, 2016-April, 2017. The protocol of this study was approved by IRB and ethical committee. A total of 80 patients with COPD were included in this study, of them clinically diagnosed 40 consecutive COPD patients who were receiving both bronchodilator & inhaled corticosteroids were recruited as case group and clinically diagnosed 40 consecutive COPD patients receiving only bronchodilator without inhaled corticosteroid/systemic steroid were recruited as control, group. Spirometry was done for confirmation and staging of COPD according to GOLD at indoor and OPD patients of Department of Internal Medicine, BSMMU. Results: In case group, the inhaled corticosteroid dose (5000) was counted 02 (5%) and the mean of FPG value was 6.25±1.34, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of FPG value was 5.7±1.58, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of FPG value was 6.58±2.24. The total FPG mean of the doses was 5.97±1.78. Among case group according to inhaled corticosteroid dose in case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of 2HABF value was 9.65±3.18, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of 2HABF value was 8.71±2.84, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of 2HABF value was 9.51±2.9. The total mean of 2HABF value of the doses was 8.98±2.82. In case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of HbA1C value was 5.85±1.06, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of HbA1C value was 6.07±0.7, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of HbA1C value was 6.7±0.74. The total mean of HbA1C value of the doses was 6.23±0.77. Conclusion: We had found that 32% of cases and 7.5% of control group were diagnosed as diabetic when fasting plasma glucose taken into account, while in case of 2 hours after breakfast plasma sugar the number were 32.5% and 10% respectively and in case of HbA1c the number were 23.5% and 10% respectively.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease
AU  - Mohammad Abul Kalam Azad Khan
AU  - Kabirul Hasan Bin Rakib
AU  - Md. Saiful Islam Patwary
AU  - Mohammad Mahmudur Rahman Chowdhury
AU  - Abu Salah Mohammamed Sirajum Munir
AU  - Sohel Ahmed
AU  - Mohammad Ashif Iqbal
AU  - Mohammad Mushahidul Islam
AU  - Md. Abdur Rahim
Y1  - 2021/10/12
PY  - 2021
N1  - https://doi.org/10.11648/j.ajim.20210905.14
DO  - 10.11648/j.ajim.20210905.14
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 236
EP  - 243
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20210905.14
AB  - Introduction: Inhaled corticosteroids effective medications for the treatment of asthma. Higher doses of inhaled fluticasone (1000 μgm / day) are commonly used in COPD. Such high doses have been associate with significant systemic effects such as pneumonia, glaucoma, cataracts, adrenal suppression and accelerated bone turnover. Aim of the study: The aim of the study was to evaluate the association between different doses of inhaled corticosteroids (Fluticasone Propionate µgm / day) and glycaemic status in Patients with Chronic Obstructive Pulmonary Disease. Material & Methods: This was a cross-sectional analytical study. This study was conducted at the department of Internal Medicine in Bangobandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, during May, 2016-April, 2017. The protocol of this study was approved by IRB and ethical committee. A total of 80 patients with COPD were included in this study, of them clinically diagnosed 40 consecutive COPD patients who were receiving both bronchodilator & inhaled corticosteroids were recruited as case group and clinically diagnosed 40 consecutive COPD patients receiving only bronchodilator without inhaled corticosteroid/systemic steroid were recruited as control, group. Spirometry was done for confirmation and staging of COPD according to GOLD at indoor and OPD patients of Department of Internal Medicine, BSMMU. Results: In case group, the inhaled corticosteroid dose (5000) was counted 02 (5%) and the mean of FPG value was 6.25±1.34, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of FPG value was 5.7±1.58, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of FPG value was 6.58±2.24. The total FPG mean of the doses was 5.97±1.78. Among case group according to inhaled corticosteroid dose in case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of 2HABF value was 9.65±3.18, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of 2HABF value was 8.71±2.84, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of 2HABF value was 9.51±2.9. The total mean of 2HABF value of the doses was 8.98±2.82. In case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of HbA1C value was 5.85±1.06, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of HbA1C value was 6.07±0.7, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of HbA1C value was 6.7±0.74. The total mean of HbA1C value of the doses was 6.23±0.77. Conclusion: We had found that 32% of cases and 7.5% of control group were diagnosed as diabetic when fasting plasma glucose taken into account, while in case of 2 hours after breakfast plasma sugar the number were 32.5% and 10% respectively and in case of HbA1c the number were 23.5% and 10% respectively.
VL  - 9
IS  - 5
ER  -

Copy | Download

Author Information

Mohammad Abul Kalam Azad Khan

Department of Internal Medicine, National Institute of Cardiovascular Diseases (NICVD), Sher E, Banglanagar, Dhaka
Kabirul Hasan Bin Rakib

Department of Medicine, Mugda Medical College Hospital, Mugda, Dhaka, Bangladesh
Md. Saiful Islam Patwary

Department of Medicine, Chandpur Medical College, Chandpur, Bangladesh
Mohammad Mahmudur Rahman Chowdhury

Department of Medicine, Chottogram Medical College, Chottogram, Bangladesh
Abu Salah Mohammamed Sirajum Munir

Department of Medicine, Mugda Medical College, Mugda, Dhaka, Bangladesh
Sohel Ahmed

Department of Medicine, 250 Bedded General Hospital, Chandpur, Bangladesh
Mohammad Ashif Iqbal

Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Mohakhali, Dhaka, Bangladesh
Mohammad Mushahidul Islam

Department of Medicine, Sheikh Hasina Medical College, Jamalpur, Bangladesh
Md. Abdur Rahim

Department of Internal Medicine, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mohammad Abul Kalam Azad Khan, Kabirul Hasan Bin Rakib, Md. Saiful Islam Patwary, Mohammad Mahmudur Rahman Chowdhury, Abu Salah Mohammamed Sirajum Munir, et al. (2021). An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Internal Medicine, 9(5), 236-243. https://doi.org/10.11648/j.ajim.20210905.14

Copy | Download

ACS Style

Mohammad Abul Kalam Azad Khan; Kabirul Hasan Bin Rakib; Md. Saiful Islam Patwary; Mohammad Mahmudur Rahman Chowdhury; Abu Salah Mohammamed Sirajum Munir, et al. An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Intern. Med. 2021, 9(5), 236-243. doi: 10.11648/j.ajim.20210905.14

Copy | Download

AMA Style

Mohammad Abul Kalam Azad Khan, Kabirul Hasan Bin Rakib, Md. Saiful Islam Patwary, Mohammad Mahmudur Rahman Chowdhury, Abu Salah Mohammamed Sirajum Munir, et al. An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease. Am J Intern Med. 2021;9(5):236-243. doi: 10.11648/j.ajim.20210905.14

Copy | Download

@article{10.11648/j.ajim.20210905.14,
  author = {Mohammad Abul Kalam Azad Khan and Kabirul Hasan Bin Rakib and Md. Saiful Islam Patwary and Mohammad Mahmudur Rahman Chowdhury and Abu Salah Mohammamed Sirajum Munir and Sohel Ahmed and Mohammad Ashif Iqbal and Mohammad Mushahidul Islam and Md. Abdur Rahim},
  title = {An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease},
  journal = {American Journal of Internal Medicine},
  volume = {9},
  number = {5},
  pages = {236-243},
  doi = {10.11648/j.ajim.20210905.14},
  url = {https://doi.org/10.11648/j.ajim.20210905.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20210905.14},
  abstract = {Introduction: Inhaled corticosteroids effective medications for the treatment of asthma. Higher doses of inhaled fluticasone (1000 μgm / day) are commonly used in COPD. Such high doses have been associate with significant systemic effects such as pneumonia, glaucoma, cataracts, adrenal suppression and accelerated bone turnover. Aim of the study: The aim of the study was to evaluate the association between different doses of inhaled corticosteroids (Fluticasone Propionate µgm / day) and glycaemic status in Patients with Chronic Obstructive Pulmonary Disease. Material & Methods: This was a cross-sectional analytical study. This study was conducted at the department of Internal Medicine in Bangobandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, during May, 2016-April, 2017. The protocol of this study was approved by IRB and ethical committee. A total of 80 patients with COPD were included in this study, of them clinically diagnosed 40 consecutive COPD patients who were receiving both bronchodilator & inhaled corticosteroids were recruited as case group and clinically diagnosed 40 consecutive COPD patients receiving only bronchodilator without inhaled corticosteroid/systemic steroid were recruited as control, group. Spirometry was done for confirmation and staging of COPD according to GOLD at indoor and OPD patients of Department of Internal Medicine, BSMMU. Results: In case group, the inhaled corticosteroid dose (5000) was counted 02 (5%) and the mean of FPG value was 6.25±1.34, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of FPG value was 5.7±1.58, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of FPG value was 6.58±2.24. The total FPG mean of the doses was 5.97±1.78. Among case group according to inhaled corticosteroid dose in case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of 2HABF value was 9.65±3.18, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of 2HABF value was 8.71±2.84, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of 2HABF value was 9.51±2.9. The total mean of 2HABF value of the doses was 8.98±2.82. In case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of HbA1C value was 5.85±1.06, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of HbA1C value was 6.07±0.7, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of HbA1C value was 6.7±0.74. The total mean of HbA1C value of the doses was 6.23±0.77. Conclusion: We had found that 32% of cases and 7.5% of control group were diagnosed as diabetic when fasting plasma glucose taken into account, while in case of 2 hours after breakfast plasma sugar the number were 32.5% and 10% respectively and in case of HbA1c the number were 23.5% and 10% respectively.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - An Association Between Different Doses of Inhaled Corticosteroids and Glycaemic Status in Patients with Chronic Obstructive Pulmonary Disease
AU  - Mohammad Abul Kalam Azad Khan
AU  - Kabirul Hasan Bin Rakib
AU  - Md. Saiful Islam Patwary
AU  - Mohammad Mahmudur Rahman Chowdhury
AU  - Abu Salah Mohammamed Sirajum Munir
AU  - Sohel Ahmed
AU  - Mohammad Ashif Iqbal
AU  - Mohammad Mushahidul Islam
AU  - Md. Abdur Rahim
Y1  - 2021/10/12
PY  - 2021
N1  - https://doi.org/10.11648/j.ajim.20210905.14
DO  - 10.11648/j.ajim.20210905.14
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 236
EP  - 243
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20210905.14
AB  - Introduction: Inhaled corticosteroids effective medications for the treatment of asthma. Higher doses of inhaled fluticasone (1000 μgm / day) are commonly used in COPD. Such high doses have been associate with significant systemic effects such as pneumonia, glaucoma, cataracts, adrenal suppression and accelerated bone turnover. Aim of the study: The aim of the study was to evaluate the association between different doses of inhaled corticosteroids (Fluticasone Propionate µgm / day) and glycaemic status in Patients with Chronic Obstructive Pulmonary Disease. Material & Methods: This was a cross-sectional analytical study. This study was conducted at the department of Internal Medicine in Bangobandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, during May, 2016-April, 2017. The protocol of this study was approved by IRB and ethical committee. A total of 80 patients with COPD were included in this study, of them clinically diagnosed 40 consecutive COPD patients who were receiving both bronchodilator & inhaled corticosteroids were recruited as case group and clinically diagnosed 40 consecutive COPD patients receiving only bronchodilator without inhaled corticosteroid/systemic steroid were recruited as control, group. Spirometry was done for confirmation and staging of COPD according to GOLD at indoor and OPD patients of Department of Internal Medicine, BSMMU. Results: In case group, the inhaled corticosteroid dose (5000) was counted 02 (5%) and the mean of FPG value was 6.25±1.34, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of FPG value was 5.7±1.58, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of FPG value was 6.58±2.24. The total FPG mean of the doses was 5.97±1.78. Among case group according to inhaled corticosteroid dose in case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of 2HABF value was 9.65±3.18, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of 2HABF value was 8.71±2.84, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of 2HABF value was 9.51±2.9. The total mean of 2HABF value of the doses was 8.98±2.82. In case group, the inhaled corticosteroid dose (500) was counted 02 (5%) and the mean of HbA1C value was 5.85±1.06, the inhaled corticosteroid dose (1000) was counted 27 (67.5%) and the mean of HbA1C value was 6.07±0.7, the inhaled corticosteroid dose (2000) was counted 11 (27.5%) and the mean of HbA1C value was 6.7±0.74. The total mean of HbA1C value of the doses was 6.23±0.77. Conclusion: We had found that 32% of cases and 7.5% of control group were diagnosed as diabetic when fasting plasma glucose taken into account, while in case of 2 hours after breakfast plasma sugar the number were 32.5% and 10% respectively and in case of HbA1c the number were 23.5% and 10% respectively.
VL  - 9
IS  - 5
ER  -

Copy | Download